Targeted therapy after surgery for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding a targeted drug (nimotuzumab) to standard chemotherapy after surgery can help prevent pancreatic cancer from coming back. It is designed for people who have had their pancreatic cancer completely or nearly completely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had surgery to remove your pancreatic cancer, and the margins were clear or nearly clear.
- You have not had chemotherapy or radiation before your surgery.
- You are well enough to get out of bed and take care of yourself (ECOG 0 or 1).
- Your blood counts and liver and kidney function are within acceptable ranges.
- You are willing to use birth control if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
This trial tests adding nimotuzumab (a targeted therapy) to standard chemotherapy for people whose pancreatic cancer was completely removed with surgery. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests a new chemotherapy combination after surgery for pancreatic cancer to see if it helps prevent the cancer from coming back. It compares the new treatment to a standard one.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.